Easom Eric's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Nov 7, 2022
- Accession no.
- 0000899243-22-035311
- Filed
- Nov 7, 2022
- Trade date
- Nov 3-7, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $558.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Easom EricCIK 0001914503 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2022 | Common Stock | SSaleDisposed | −11,082 | $15.67 | −$173,654.94 | 29,021 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −3,083 | $16.02 | −$49,389.66 | 25,938 | Direct | |
| Nov 4, 2022 | Common Stock | SSaleDisposed | −8,828 | $15.80 | −$139,482.4 | 17,110 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −10,167 | $15.90 | −$161,655.3 | 6,943 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −2,036 | $16.72 | −$34,041.92 | 4,907 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.